Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease

Robert Hendel, John J. Layden, Jeffrey A. Leppo

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Exercise testing alone or in combination with thallium scintigraphy has significant prognostic value. In contrast, dipyridamole thallium imaging is not dependent on patients achieving adequate levels of exercise, but no long-term prognostic studies have been reported. Accordingly, imaging results of 516 consecutive patients referred for dipyridamole thallium studies were correlated with subsequent cardiac events, death (n = 23) and myocardial infarction (n = 43) over a mean follow-up period of 21 months. Patients with a history of congestive heart failure, prior myocardial infarction, diabetes mellitus or abnormal scans were significantly more likely to have a cardiac event (p < 0.03). With use of logistic regression analysis, an abnormal scan was an independent and significant predictor of subsequent myocardial infarction or cardiac death and increased the relative risk of any event more than threefold. The presence of redistribution on thallium scanning further increased the risk of a cardiac event. Survival analysis demonstrated a significant difference between patients with an abnormal or normal thallium scan over a 30 month period. In conclusion, dipyridamole thallium scintigraphy demonstrates prognostic value in a large unselected population and may be an adequate clinical alternative to physiologic exercise testing in the evaluation of coronary heart disease.

Original languageEnglish
Pages (from-to)109-116
Number of pages8
JournalJournal of the American College of Cardiology
Volume15
Issue number1
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Dipyridamole
Thallium
Radionuclide Imaging
Myocardial Ischemia
Myocardial Infarction
Exercise
Survival Analysis
Coronary Disease
Diabetes Mellitus
Heart Failure
Logistic Models
Regression Analysis
Population

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease. / Hendel, Robert; Layden, John J.; Leppo, Jeffrey A.

In: Journal of the American College of Cardiology, Vol. 15, No. 1, 01.01.1990, p. 109-116.

Research output: Contribution to journalArticle

Hendel, Robert ; Layden, John J. ; Leppo, Jeffrey A. / Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease. In: Journal of the American College of Cardiology. 1990 ; Vol. 15, No. 1. pp. 109-116.
@article{0ef8820b5cfa4f6295d95eb8b0fecace,
title = "Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease",
abstract = "Exercise testing alone or in combination with thallium scintigraphy has significant prognostic value. In contrast, dipyridamole thallium imaging is not dependent on patients achieving adequate levels of exercise, but no long-term prognostic studies have been reported. Accordingly, imaging results of 516 consecutive patients referred for dipyridamole thallium studies were correlated with subsequent cardiac events, death (n = 23) and myocardial infarction (n = 43) over a mean follow-up period of 21 months. Patients with a history of congestive heart failure, prior myocardial infarction, diabetes mellitus or abnormal scans were significantly more likely to have a cardiac event (p < 0.03). With use of logistic regression analysis, an abnormal scan was an independent and significant predictor of subsequent myocardial infarction or cardiac death and increased the relative risk of any event more than threefold. The presence of redistribution on thallium scanning further increased the risk of a cardiac event. Survival analysis demonstrated a significant difference between patients with an abnormal or normal thallium scan over a 30 month period. In conclusion, dipyridamole thallium scintigraphy demonstrates prognostic value in a large unselected population and may be an adequate clinical alternative to physiologic exercise testing in the evaluation of coronary heart disease.",
author = "Robert Hendel and Layden, {John J.} and Leppo, {Jeffrey A.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/0735-1097(90)90184-Q",
language = "English",
volume = "15",
pages = "109--116",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease

AU - Hendel, Robert

AU - Layden, John J.

AU - Leppo, Jeffrey A.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Exercise testing alone or in combination with thallium scintigraphy has significant prognostic value. In contrast, dipyridamole thallium imaging is not dependent on patients achieving adequate levels of exercise, but no long-term prognostic studies have been reported. Accordingly, imaging results of 516 consecutive patients referred for dipyridamole thallium studies were correlated with subsequent cardiac events, death (n = 23) and myocardial infarction (n = 43) over a mean follow-up period of 21 months. Patients with a history of congestive heart failure, prior myocardial infarction, diabetes mellitus or abnormal scans were significantly more likely to have a cardiac event (p < 0.03). With use of logistic regression analysis, an abnormal scan was an independent and significant predictor of subsequent myocardial infarction or cardiac death and increased the relative risk of any event more than threefold. The presence of redistribution on thallium scanning further increased the risk of a cardiac event. Survival analysis demonstrated a significant difference between patients with an abnormal or normal thallium scan over a 30 month period. In conclusion, dipyridamole thallium scintigraphy demonstrates prognostic value in a large unselected population and may be an adequate clinical alternative to physiologic exercise testing in the evaluation of coronary heart disease.

AB - Exercise testing alone or in combination with thallium scintigraphy has significant prognostic value. In contrast, dipyridamole thallium imaging is not dependent on patients achieving adequate levels of exercise, but no long-term prognostic studies have been reported. Accordingly, imaging results of 516 consecutive patients referred for dipyridamole thallium studies were correlated with subsequent cardiac events, death (n = 23) and myocardial infarction (n = 43) over a mean follow-up period of 21 months. Patients with a history of congestive heart failure, prior myocardial infarction, diabetes mellitus or abnormal scans were significantly more likely to have a cardiac event (p < 0.03). With use of logistic regression analysis, an abnormal scan was an independent and significant predictor of subsequent myocardial infarction or cardiac death and increased the relative risk of any event more than threefold. The presence of redistribution on thallium scanning further increased the risk of a cardiac event. Survival analysis demonstrated a significant difference between patients with an abnormal or normal thallium scan over a 30 month period. In conclusion, dipyridamole thallium scintigraphy demonstrates prognostic value in a large unselected population and may be an adequate clinical alternative to physiologic exercise testing in the evaluation of coronary heart disease.

UR - http://www.scopus.com/inward/record.url?scp=0025174615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025174615&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(90)90184-Q

DO - 10.1016/0735-1097(90)90184-Q

M3 - Article

VL - 15

SP - 109

EP - 116

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 1

ER -